<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Etanercept, a fully human soluble recombinant p75 <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF) receptor that blocks the binding of TNF to cell surface receptors, is approved for the treatment of psoriatic <z:hpo ids='HP_0001369'>arthritis</z:hpo> and other rheumatic conditions in the US and Europe </plain></SENT>
<SENT sid="1" pm="."><plain>Ever since the introduction of anti-TNF treatment in patients with inflammatory <z:hpo ids='HP_0002960'>autoimmune diseases</z:hpo>, there have been concerns about a possible <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-promoting effect of such a measure </plain></SENT>
<SENT sid="2" pm="."><plain>We report a rare case of leukemic phase of follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> in a 62-year-old man with moderate-to-severe plaque <z:hpo ids='HP_0003765'>psoriasis</z:hpo> receiving long-term treatment with etanercept for 3 years </plain></SENT>
<SENT sid="3" pm="."><plain>Although the association is intriguing, no causal relationship is suggested </plain></SENT>
</text></document>